Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

SIMPLIFY Study Group

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology